Clinical Translation: Large-Animal Radiolabeling and In Vivo Imaging Platform
Bridging Translational Gaps in Drug Development
Clinical translation remains a critical challenge in drug development, particularly due to limited predictability of preclinical data. Conventional ex vivo assays and rodent models often fail to accurately predict human pharmacokinetics (PK) and tissue biodistribution because of interspecies physiological differences.
Prisys Biotechnologies, an AAALAC-accredited preclinical CRO, has established a translational research framework centered on non-human primate (NHP) models. Within this framework, radiolabeling technologies combined with in vivo medical imaging provide a direct approach to obtaining dynamic and quantitative data on drug distribution in living systems.
Clinical-Grade Imaging Infrastructure and Analytical Expertise
To improve the translational relevance of preclinical studies, Prisys Biotechnologies operates clinical-grade imaging systems, including PET-CT and SPECT-CT, enabling high-resolution, whole-body imaging in large animal models such as NHPs.
To support ADME studies, the facility is equipped with customized metabolic cages designed for large animals, allowing controlled collection of biological samples for absorption, distribution, metabolism, and excretion analysis.
Image acquisition and interpretation are conducted by a dedicated imaging team composed of clinicians with extensive experience in radiology and interventional medicine. This ensures standardized imaging procedures and enhances the clinical interpretability of the data.
Radiolabeling Strategies and In Vivo Tracking Applications
The Biodistribution Imaging Service platform supports radiolabeling of a wide range of compounds using multiple isotope systems, including:
- Positron-emitting isotopes (e.g., ¹⁸F, ⁸⁹Zr, ¹¹C)
- Single-photon isotopes (e.g., ¹³¹I, ⁹⁹mTc)
- Therapeutic radionuclides
These labeling approaches are applicable to small molecules, monoclonal antibodies, and cell-based therapies.
For example, in immunology and oncology studies, immune cells such as dendritic cells (DCs) and T cells can be labeled with ⁸⁹Zr and tracked in vivo using PET-CT in NHP models. This enables real-time evaluation of cell migration, tissue distribution, and target engagement.
Translational Applications Across Disease Areas
Radiolabeled imaging in large-animal models supports quantitative and non-invasive assessment of drug behavior across multiple therapeutic areas:
Cardiovascular and Metabolic Imaging
PET tracers such as ¹³N-NH₃·H₂O enable myocardial perfusion imaging, while glucose metabolism can be assessed using PET-CT. These approaches provide functional endpoints for cardiovascular disease models.
Central Nervous System (CNS) Imaging
For neurodegenerative disease research, PET tracers such as ¹⁸F-FP-CIT allow quantitative imaging of dopamine transporter activity, supporting evaluation of disease progression and target engagement.
Multimodal Hybrid Imaging
Hybrid PET/MRI integrates metabolic sensitivity from PET with high-resolution anatomical imaging from MRI. This approach supports comprehensive evaluation of complex or multi-centric lesions through combined qualitative and quantitative analysis.
Conclusion
By integrating NHP models with clinical-grade radiolabeling and imaging technologies, Prisys Biotechnologies provides in vivo data on drug biodistribution and pharmacokinetics with improved translational relevance.
This platform supports informed decision-making in drug development by enabling direct observation of drug behavior in physiologically relevant systems. Customized study designs can be developed based on specific research objectives and therapeutic areas.
FAQ
Q: Why are large-animal imaging studies important for clinical translation?
A: Large-animal models, particularly non-human primates, provide physiological and metabolic characteristics closer to humans. When combined with in vivo imaging, they enable more accurate prediction of human pharmacokinetics and tissue distribution.
Q: What types of drugs can be studied using radiolabeling and imaging?
A: Radiolabeling can be applied to small molecules, biologics such as monoclonal antibodies, and cell-based therapies. This allows real-time tracking of drug distribution and target engagement in vivo.
Q: How does PET/MRI improve data quality compared to single-modality imaging?
A: PET/MRI combines metabolic information from PET with high-resolution anatomical data from MRI. This enables more precise localization and quantification of drug distribution, particularly in complex disease settings.
